Studies have identified several contributing factors to thrombosis in ITP, such as age, metabolic syndrome, smoking, the proinflammatory state, higher number of reticulated platelets, presence of antiphospholipid antibodies, and ITP treatments including intravenous immunoglobulin, corticosteroids, thrombopoietin-receptor agonists (TPO-RAs), and splenectomy [2, 3, 8–10]. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.